Exploring enzyme-instructed self-assembly (EISA) for targeting osteoblastic metastasis of prostate cancer
探索酶指导自组装(EISA)以靶向前列腺癌的成骨细胞转移
基本信息
- 批准号:10044030
- 负责人:
- 金额:$ 43.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-01 至 2022-07-31
- 项目状态:已结题
- 来源:
- 关键词:Acid PhosphataseAlkaline PhosphataseAndrogensAnimal ModelBiochemical ReactionBiological AssayCancer EtiologyCell modelCellsCellular AssayCessation of lifeCoculture TechniquesDevelopmentDiseaseDistant MetastasisEnzyme InhibitionEnzymesHormonesImageIn SituLeadMalignant NeoplasmsMalignant neoplasm of prostateMedical centerMetastatic Prostate CancerMolecularMolecular TargetNMR SpectroscopyNanotechnologyNeoplasm MetastasisOperative Surgical ProceduresOsteoblastsPeptide SynthesisPeptidesPhasePhenotypeProcessProstate Cancer therapyRadiationReactionResearchResistanceSiteSolidStructureTestingTherapeuticUnited Statesandrogen deprivation therapyanti-cancer therapeuticbasebonecancer cellcancer therapycastration resistant prostate cancerclinically relevantdesignend stage diseaseenzyme activityenzyme substrateimproved outcomeinnovationmalemenmortalitynanofibrillarnanoparticlenew therapeutic targetnovelnovel strategiesoverexpressionprogramsprostate cancer cellprostate cancer metastasisprostate cancer progressionself assemblysmall moleculesuccesstargeted agenttargeted treatmenttumortumor microenvironment
项目摘要
Abstract
Prostate cancer (PCa) remains as the most frequent cancer and the second leading cause of cancer
mortality among U.S. males that are mainly associated with metastatic diseases. Bone is the major site of distant
metastases of PCa. Although androgen deprivation therapy (ADT) is effective for treating hormone naive PCa,
the onset of metastatic castration-resistant prostate cancer (mCRPC) confers androgen resistant phenotypes,
which is the end stage of disease without cure. Thus, developing novel approaches for treating mCRPC is
urgently needed. It is well known the reciprocal interaction between PCa and bone microenvironment resulted in
unique osteoblastic reaction that further promotes PCa progression. Thus, we hypothesize that dual targeting
osteoblast and PCa cells should lead to a novel single agent as an effective targeted therapy for mCRPC.
Therefore, we propose to explore enzyme-instructed self-assembly (EISA) for targeting osteoblastic mCRPC.
The proposed research is to develop the EISA substrates that can undergo EISA by the actions of alkaline
phosphatase (ALPL) and acid phosphatase (ACPP) and to examine their efficacy in cell assays. This
research program will focus on three specific aims: Aim 1, design and synthesis of EISA substrates of ALPL and
ACPP; Aim 2, characterizing the EISA substrates of ALPL and ACPP and determining their activities in the co-
culture of osteoblast and mCRPC cells; and Aim 3, examining the efficacy of the EISA substrates for inhibiting
mCRPC in clinically relevant animal models. The rigor of prior research is that (i) it is well documented that
overexpression of ALPL is the feature of osteoblastic metastases and overexpression of ACPP is the
feature of PCa and (ii) our preliminary results show that EISA catalyzed by ALPL selectively inhibits
osteoblast model cells and EISA catalyzed by ACPP selectively inhibit CRPC cells. The success of the
proposed studies will contribute to the development of new molecular targeting agents based on ALPL and ACPP
overexpressed during the process of metastasis of mCRPC in bone, which may ultimately lead to breakthrough
in treating mCRPC.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(2)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jer-Tsong Hsieh其他文献
Jer-Tsong Hsieh的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jer-Tsong Hsieh', 18)}}的其他基金
Targeting KDM4B, a novel alternative splicing regulator, in castration-resistant prostate cancer (CRPC)
靶向 KDM4B(一种新型选择性剪接调节因子)治疗去势抵抗性前列腺癌 (CRPC)
- 批准号:
10312132 - 财政年份:2018
- 资助金额:
$ 43.05万 - 项目类别:
Targeting KDM4B, a novel alternative splicing regulator, in castration-resistant prostate cancer (CRPC)
靶向 KDM4B(一种新型选择性剪接调节因子)治疗去势抵抗性前列腺癌 (CRPC)
- 批准号:
10116972 - 财政年份:2018
- 资助金额:
$ 43.05万 - 项目类别:
Developing targeted therapy with prostate cancer specific nanomedicine
开发前列腺癌特异性纳米药物的靶向治疗
- 批准号:
9325475 - 财政年份:2013
- 资助金额:
$ 43.05万 - 项目类别:
Developing targeted therapy with prostate cancer specific nanomedicine
开发前列腺癌特异性纳米药物的靶向治疗
- 批准号:
8615933 - 财政年份:2013
- 资助金额:
$ 43.05万 - 项目类别:
Targeting aggressive prostate cancer with novel theranostic nanomedicine
利用新型治疗诊断纳米药物治疗侵袭性前列腺癌
- 批准号:
8509520 - 财政年份:2011
- 资助金额:
$ 43.05万 - 项目类别:
Targeting aggressive prostate cancer with novel theranostic nanomedicine
利用新型治疗诊断纳米药物治疗侵袭性前列腺癌
- 批准号:
8336823 - 财政年份:2011
- 资助金额:
$ 43.05万 - 项目类别:
Targeting aggressive prostate cancer with novel theranostic nanomedicine
利用新型治疗诊断纳米药物治疗侵袭性前列腺癌
- 批准号:
8892816 - 财政年份:2011
- 资助金额:
$ 43.05万 - 项目类别:
Targeting aggressive prostate cancer with novel theranostic nanomedicine
利用新型治疗诊断纳米药物治疗侵袭性前列腺癌
- 批准号:
8703512 - 财政年份:2011
- 资助金额:
$ 43.05万 - 项目类别:
Targeting aggressive prostate cancer with novel theranostic nanomedicine
利用新型治疗诊断纳米药物治疗侵袭性前列腺癌
- 批准号:
8092399 - 财政年份:2011
- 资助金额:
$ 43.05万 - 项目类别:
The role of CAR and its application in bladder cancer
CAR的作用及其在膀胱癌中的应用
- 批准号:
7013967 - 财政年份:2003
- 资助金额:
$ 43.05万 - 项目类别:
相似海外基金
The role of tissue nonspecific alkaline phosphatase in brain endothelial cell homeostasis
组织非特异性碱性磷酸酶在脑内皮细胞稳态中的作用
- 批准号:
10220574 - 财政年份:2021
- 资助金额:
$ 43.05万 - 项目类别:
Post-Transcriptional Processing of the Small Intestinal Alkaline Phosphatase in the Postnatal Developing Pig
产后发育猪小肠碱性磷酸酶的转录后加工
- 批准号:
RGPIN-2016-05827 - 财政年份:2021
- 资助金额:
$ 43.05万 - 项目类别:
Discovery Grants Program - Individual
The role of tissue nonspecific alkaline phosphatase in brain endothelial cell homeostasis
组织非特异性碱性磷酸酶在脑内皮细胞稳态中的作用
- 批准号:
10413987 - 财政年份:2021
- 资助金额:
$ 43.05万 - 项目类别:
The role of tissue nonspecific alkaline phosphatase in brain endothelial cell homeostasis
组织非特异性碱性磷酸酶在脑内皮细胞稳态中的作用
- 批准号:
10601067 - 财政年份:2021
- 资助金额:
$ 43.05万 - 项目类别:
Selective targeting of human alkaline phosphatase isozymes
选择性靶向人碱性磷酸酶同工酶
- 批准号:
10359823 - 财政年份:2020
- 资助金额:
$ 43.05万 - 项目类别:
Dietary induction of intestinal alkaline phosphatase intended to detoxify endotoxin and analysis of its mechanism of action.
膳食诱导肠道碱性磷酸酶解毒内毒素及其作用机制分析。
- 批准号:
20K05936 - 财政年份:2020
- 资助金额:
$ 43.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Functional analysis of alkaline phosphatase, a stem cell marker, using human deciduous dental pulp cells derived from the patient with Hypophosphatasia (HPP)
使用源自低磷酸酯酶症 (HPP) 患者的人乳牙牙髓细胞对干细胞标记物碱性磷酸酶进行功能分析
- 批准号:
20K10210 - 财政年份:2020
- 资助金额:
$ 43.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding the role of tissue non-specific alkaline phosphatase in osteogenesis for the therapy of hypophosphatasia.
了解组织非特异性碱性磷酸酶在成骨作用中的作用,以治疗低磷酸酯酶症。
- 批准号:
20K16894 - 财政年份:2020
- 资助金额:
$ 43.05万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Selective targeting of human alkaline phosphatase isozymes
选择性靶向人碱性磷酸酶同工酶
- 批准号:
10117265 - 财政年份:2020
- 资助金额:
$ 43.05万 - 项目类别:
Post-Transcriptional Processing of the Small Intestinal Alkaline Phosphatase in the Postnatal Developing Pig
产后发育猪小肠碱性磷酸酶的转录后加工
- 批准号:
RGPIN-2016-05827 - 财政年份:2020
- 资助金额:
$ 43.05万 - 项目类别:
Discovery Grants Program - Individual














{{item.name}}会员




